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Abstract
Purpose In malignant tumors, predictive markers have
been developed with respect to targeted therapies. One of
the Wrst targeted therapies was the hormone-blocking treat-
ment of tumors of the male and female reproductive
system. A typical therapy in breast cancer is the use of the
selective estrogen receptor modulator, tamoxifen. How-
ever, only some of the patients, positive for the target mole-
cules, respond to the selected therapy. It would, therefore,
be highly desirable to have a tool to promptly assess the
therapeutic eYcacy of the applied agent in the individual
patient.
Methods Longitudinal observation of CETC provides a
unique tool for monitoring therapy response. About 178
patients with breast cancer were followed prospectively
during hormone therapy, requiring only 1 ml of peripheral
blood, using a Xuorochrome-labeled antibody against sur-
face-epithelial antigen. Image analysis allowed CETC num-
bers to be calculated in relation to blood volume and
monitoring over the entire course of treatment.
Results A more than tenfold increase in CETC during
therapy was a strong indicator of looming relapse
(P = 0.0001 hazard ratio 5.5; 95% conWdence interval
1,297–23,626), and a Cox regression analysis of age, tumor
size, receptor expression, nodal status and previous treat-
ment resulted in a regression model, in which CETC behav-
ior was the parameter with the highest independent
correlation to relapse-free survival.
Conclusions The change in the number of CETC
(increase or decrease) may, in the future, be used to guide
therapy in order to change to other available treatment
options in good time.
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Purpose
Malignant tumors of the male or female reproductive
system, especially of the prostate in men and of the breast
in women, are among the most frequent malignancies,
accounting for about 310,000 deaths per year in the devel-
oped world. However, in most cases, patients do not die
from the primary tumor but from metastases seeded from
the tumor into vital organs. This has led to the assumption
that cells are released from the primary tumor, which then
migrate via the blood to distant loci where they can settle
and re-grow. In breast cancer, adjuvant chemotherapy pro-
tocols have been developed aimed at eliminating these
cells. Indeed, adjuvant chemotherapy has retained its rele-
vance after 30 years of observation (Bonadonna et al.
2005), indicating that these remnant cells present after
breast surgery are the cells that give rise to later metastases.
Several puriWcation and enrichment methods have been
used to search for such cells in bone marrow and blood, and
the debate continues as to the “true” number of such cells
and micrometastases. All of these methods, however, have
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major drawbacks: density gradient puriWcation with
interphase recovery and several washing steps may lead to
a signiWcant loss of relevant cells (Fleisher and Marti 2001)
and magnetic bead enrichment as used by the CellSearch
system may lead to massive cell destruction, leaving
mainly cell debris (Comans et al. 2010). Omitting all
enrichment procedures, we have developed a method
termed MAINTRAC®, with which we were able to analyze
the presence of viable cells in diVerent stages of disease and
their response to the applied therapies. The commercially
available Cellsearch method, which probably due to the
above-mentioned massive cell loss, detects >1 viable cells
only in about 10% of patients with primary breast cancer
(Bidard et al. 2010), whereas this was true in 3% of normal
donors (Miller et al. 2010). We were able to detect CETC
in 92% of all patients with primary breast cancer and in 3%
of healthy donors (Pachmann et al. 2005).
It is hypothesized that all CETC from the primary tumor
are rapidly eliminated from the blood (Molloy and van’t
Veer 2008) and that subsequently detected tumor cells must
be continuously spread from occult micrometastatic loci
(Meng et al. 2004). We have, however, shown that CETC
are present in patients with cancer already before treatment
(Camara et al. 2007), but additional cells can be dissemi-
nated by surgery (Camara et al. 2006). Part of these cells,
after surgery, are rapidly eliminated (Camara et al. 2006)
but remnant cells can be present in the blood at constant
numbers over long times (Pachmann 2005), indicating that
they are only rarely completely eliminated and can survive
and re-circulate in peripheral blood.
CETC can be reduced or eliminated by systemic chemo-
therapy, and this correlates with a good prognosis, indica-
tive of the role of these cells play in metastasis formation
(Lobodasch et al. 2007). A reappearance or increase in
CETC already during chemotherapy, possibly also through
mobilization from remote loci, is associated with
poor relapse-free survival (Pachmann et al. 2008). These
re-increasing CETC obviously have a high capacity to
resettle again when released at the end of chemotherapy,
thereby giving them an advantage for re-growth into mea-
surable metastases.
Monitoring the response of CETC with this method, we
were able to conWrm results for individual patients at the
single-cell level (Pachmann et al. 2008) that had previously
only been statistically determined in large patient popula-
tions, such as the observation that adjuvant systemic che-
motherapy treatment is not necessary or not suYcient in all
patients with breast cancer (van der Hage et al. 2007) and
that estrogen receptor-negative (ER¡) patients respond bet-
ter to chemotherapy than estrogen receptor-positive (ER+)
patients (Camara et al. 2007). In this report, we have
extended our research to investigate the impact of the addi-
tion of hormones-blocking ER on CETC.
Androgens in male and estrogens in female patients can
stimulate the growth of tumor cells carrying the respective
receptors in the primary tumor as well as the metastases and
thus contribute to a fatal outcome. Agents that bind to these
receptors but that do not activate have been shown capable
of inhibiting the growth of receptor-positive tumors, pro-
viding the Wrst known targeted therapy. Such hormone-
blocking treatment has contributed to improving outcome
in patients with hormone receptor-positive tumors (Heel
et al. 1978; Senn 1968). It is not known whether anti-andro-
gens and tamoxifen can also exert inXuence on the remnant
cells circulating in the blood after complete removal of the
primary tumor. Obviously, such cells can persist for
extended periods in the host, and this can lead to the forma-
tion of distant metastases even up to 20 years afterward
(Meng et al. 2004).
A high proportion of patients with breast cancer have
estrogen receptor-positive tumors, especially in the
elderly group over 50 years. Hormone treatment has
empirically been observed to exert beneWciary results
(Bonneterre  1992) only after a long, continuous treat-
ment. This indicates that such a treatment may also inXu-
ence tumor cells in the circulation that have not settled
yet. However, some patients may not beneWt from tamox-
ifen therapy due to an enzyme defect in the tamoxifen
metabolism (Gaston and Kolesar 2008), and approxi-
mately 60% of patients with ER-positive breast cancer
who initially respond to the selective estrogen receptor
modulator tamoxifen will develop acquired resistance.
On the other hand, patients are sometimes diYcult to
convince that it is necessary to comply (Owusu et al.
2008), particularly if adverse symptoms are prevalent
(Fink et al. 2004) and immediate treatment success is not
measurable for the individual patient. In the present
report, we show that monitoring of CETC during hor-
mone treatment is possible and can contribute to better
determining the response to hormone-blocking agents
and the eYcacy of therapy.
Methods
During the recruitment interval from 2001 to 2006 in our
institution, all patients with primary breast cancer sched-
uled for SERM treatment after neoadjuvant or adjuvant
therapy or without prior chemotherapy, in total 178 sequen-
tial patients, who gave their informed consent, were
included. They were prospectively analyzed for CETC up
to 5 years of treatment with tamoxifen or, if relapse
occurred earlier, until relapse. Most patients were analyzed
for their CETC already during chemotherapy, but are
included into the present evaluation only at the start of
treatment with tamoxifen.J Cancer Res Clin Oncol (2011) 137:821–828 823
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About 1 ml of anti-coagulated peripheral blood was
obtained, according to ethics committee approval, and ana-
lyzed using the previously described microXuorimetric
method, where assay method stability of the sample and
reproducibility are extensively described (Pachmann et al.
2005). In short, in order to compensate for shipping delays,
samples were subjected to red blood cell lysis at day 2 after
blood drawing (with usually 95% viability) using 10 ml of
erythrocyte lysis solution (Qiagen, Hilden, Germany) for
10 min in the cold, spun down at 700 g and re-diluted in
1 ml of PBS. About 10 l of Xuoresceinisothiocyanate
(FITC)-conjugated mouse anti-human epithelial antibody
(HEA) (Milteny, Bergisch Gladbach Germany) and 1 l of
phycoerythrin (PE)-labeled anti-CD45 were added to
100 l of cell suspension, incubated for 15 min in the dark
and readjusted to 1 ml, and 20 l of this suspension was
used for measuring epithelial antigen-positive cells.
A deWned volume of the cell suspension was applied to a
deWned area either on adhesion slides (Menzel Gläser,
Braunschweig, Germany) or into wells of Elisa plates; the
adherent cells were measured either using a Laser Scanning
Cytometer (LSC® Compucyte Corporation, Cambridge,
MA, USA) and collecting the FITC-HEA and the PE-CD45
Xuorescence using a photomultiplier (PMT) or using image
analysis in the ScanR (Olympus, Munich, Germany). Val-
ues are displayed in scatter grams and histograms. Both
approaches enable the user to locate cells contained within
the positive population for visual examination and to take
photos and Xuoromicrographs. Figure 1a depicts an exam-
ple of the procedure. In Fig. 1b, viability of the cells was
visually detected and veriWed by propidium iodide (PI)
staining (entering exclusively dying cells), looking for
nuclear PI stain and exclusive surface EpCAM staining.
Most patients have been followed for their CETC numbers
during adjuvant or neoadjuvant treatment, if necessary.
During the subsequent maintenance therapy, CETCs were
analyzed at each visit, if possible at intervals of 3 months
and later at more extended intervals. This allowed longitu-
dinal follow-up of the CETCs for each patient. Patients
were categorized according to their behavior into those
with a more than tenfold increase or decrease over a period
of 2 years or if relapse occurred before this time. Patients
with changes less than tenfold were grouped as those with
no signiWcant change. The median relapse-free survival in
the groups with decreasing CETCs was not reached,
whereas the median relapse-free survival time for the
patients with increasing CETCs was about 4 years. If a
level of signiWcance of P = 0.001 with a power of 0.8 was
to be detected, the sample size was calculated to require 35
patients in each group, which was exceeded in both the
group with decreasing and increasing CETCs. Statistical
analyses of Kaplan–Meier relapse-free survival and the
Cox regression analysis for the confounding variables
tumor size, lymph node status, HER2/neu status, hormone
receptor status and previous chemotherapy were performed
using the SPSS program, version 16.1.
Results
The characteristics of all patients are shown in Table 1.
They were similar to the patients’ characteristics in large
studies such as the Breast International Group 1–98 trial
(Doughty 2008) with respect to age, tumor size, nodal sta-
tus and estrogen receptor positivity and frequency of
relapses. One hundred and seventeen out of 178 patients
(66%) had previously received neoadjuvant or adjuvant
chemotherapy. Patients with conWrmed HER2/neu positiv-
ity were treated with trastuzumab for 1 year. As previously
reported (Pachmann et al. 2008), most patients even after
adjuvant systemic chemotherapy still had circulating tumor
cells detectable and all 178 patients received tamoxifen for
hormone blockade. The median of CETC numbers before
hormone treatment was 3,200/ml (200–51,200/ml, 5–95%
conWdence interval). For 29 (16%) patients, only single
analyses of CETC values were available during tamoxifen
therapy, leaving 149 patients evaluable for CETC changes
during hormone-blocking maintenance treatment. About
three patients with primary metastasized breast cancer were
excluded. Cell numbers decreased in 66 (45%) and margin-
ally changed in 23 (16%) patients. A more than tenfold
increase in cell numbers in spite of systemic hormone
blockade occurred in 58 (39%) patients. Typical courses of
cell numbers from three individual patients each are shown
in Fig. 2a and b. In contrast to the sharp, more than tenfold
decrease or increase in CETC numbers seen during the
weeks of chemotherapy (left negative axis in Fig. 2a, b), the
response to hormone therapy was a slow stepwise reduction
(right positive axis) over a period of up to 4 years of
monitoring.
In total, 43/175 (25%) relapses occurred during treat-
ment with tamoxifen (8 local and 35 distant metastases), for
which CETC monitoring was available in 28/147 (19%),
indicating that the population with repeated CETC analysis
was representative for the whole patient population; 2
relapses occurred among the 66 cases with decreasing
CETC (3%), 3 of the 23 cases with marginal changes (13%)
and 21 of the 58 evaluable cases with increasing CETC dur-
ing tamoxifen treatment (36%). Patients with lacking infor-
mation from a HER2/neu analysis and the few patients for
whom hormone receptor determination was not available
were well balanced between patients in complete remission
and those in relapse.
The two patients who suVered relapse in spite of
decreasing CETC had an extremely high increase in num-
bers of CETC during surgery. Kaplan–Meier relapse-free824 J Cancer Res Clin Oncol (2011) 137:821–828
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survival curves are shown in Fig. 3. Patients with increas-
ing numbers of CETC during tamoxifen treatment had a
signiWcantly poorer relapse-free survival than patients with
decreasing CETC (P < 0.0001 hazard ratio = 5.5; 95% con-
Wdence interval 1,297–23,626) during the subsequent up to
5½ years (CR: median 850 days, minimum 9 days, maxi-
mum 3,155 days, relapses: median 723 days, minimum
175 days, maximum 8,278 days) of observation indepen-
dent of the previous neoadjuvant or adjuvant treatments.
Patients with stable or slightly undulating CETC had an
intermediate risk. If compared for known risk factors, there
was no diVerence between relapsing patients and patients in
complete continuous remission with respect to age, HER2/
neu status, estrogen receptor status or adjuvant or neoadju-
vant treatment. But patients with a relapse had a tendency
to have larger tumors (P = 0.45) and had a signiWcantly
higher frequency of positive lymph nodes (P = 0.005).
Patients who did not receive chemotherapy due to good
prognosis had a tendency (P = 0.12) to have fewer relapses
(Table 2). However, in a multivariate Cox regression
model, the increase in CETC turned out to be the most
signiWcant independent prognostic factor (Table 2).
The behavior of the CETC during the tamoxifen treat-
ment (decrease and marginal changes or increase) was also
highly predictive for the subsequent outcome of 45 patients
who were scheduled to receive aromatase inhibitors (AI)
either due to relapse (17 (38%)) or due to the new treatment
strategy of switching from tamoxifen to an AI (28 (62%))
(Fig. 4). Patients who had already shown an increase in cell
numbers during tamoxifen treatment had a poorer relapse-
free survival during treatment with AI than patients who
had responded to tamoxifen therapy with a decrease in
CETC (P = 0.004). However, there was a clear progression
and relapse-free survival advantage in patients receiving AI
after tamoxifen also in our patient sample as will be shown
in a following paper.
Conclusions
Although in patients with breast cancer the risk of relapse
is higher in the hormone receptor-negative (HR¡) group
between years 3 and 4, the hazard of recurrence for HR¡ and
HR+ patients subsequently crosses, and beyond 5 years it
Fig. 1 a Example of the procedure used for analysis of epithelial cells
in the LSC. The microscope scans a deWned area on a slide, to which a
deWned volume of cell suspension is applied. The majority of cells are
normal blood cells, showing only CD45 Xuorescence. Positively
stained green Xuorescing cells are gated in the green window. Cells in
this window can be localized again, viewed, photographed and reana-
lyzed. b Shows a typical picture of a tumor cell detectable in the Scan
R by its green Xuorescing cap, accompanied by two dead (PI-positive)
normal blood cells. In transmitted light, more live (PI-negative) blood
cells are visibleJ Cancer Res Clin Oncol (2011) 137:821–828 825
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is actually higher for HR+ patients (Saphner et al. 1996).
This means that, despite optimized treatment, eventually a
high proportion of patients, even in the HR+ group with a
relatively good prognosis, suVer relapse. Hormone recep-
tor-blocking treatment, without or after previous chemo-
therapy, has proven to be advantageous over surgery alone
in hormone-sensitive breast cancer, with tamoxifen being
the gold standard in hormone therapy (EBCTCG 1998),
and is regarded as one of the Wrst targeted therapies
improving outcome with or without previous chemother-
apy. Tamoxifen has been assumed to block the growth-
stimulating eVect of estrogen causing cells to stay in the
G1 phase of the cell cycle (Osborne 1998), whereas AI
work by inhibiting the formation of estrogen (Hind et al.
2007). Hormone treatment may also prevent tumor cells
from settling (Epstein 2005). Tamoxifen is relatively well
tolerated and cost eVective. This has prompted studies
comparing diVerent times of tamoxifen administration fol-
lowed by AI (Rabaglio et al. 2007; Mamounas et al. 2008;
Kaufmann et al. 2007), and it is not yet clear how long
either hormone therapy should be given for optimal results
(Ingle et al. 2006). Long-term tamoxifen therapy is also
Table 1 Characteristics of all 
175 patients with respect to age, 
tumor size, lymph nodes, HER2/
neu status, hormone receptor, 
complete remission/relapse/
progress, chemotherapy
Total patients 175
Mean age 55
Tumor size
T1 91 (52%)
T2> 67 (38%)
n.a. 17 (10%)
Lymph node
N0 103 (59%)
N1> 56 (32%)
n.a. 16 (9%)
Her2/neu status
Negative 83 (48%)
Positive 42 (24%)
n.a. 50 (28%)
Hormone receptor
Negative 9 (5%)
Positive 155 (89%)
n.a. 11 (6%)
Relapse/CR
Relapse 43 (25%)
CR 132 (75%)
n.a. 0 (0%)
Chemotherapy
Adj 73 (42%)
Neo 41 (23%)
None 46 (26%)
n.a. 15 (9%)
n.a. not analyzed, CR complete 
remission, adj adjuvant, neo 
neoadjuvant
Fig. 2 a and b Typical changes in cell numbers in three individual
patients each (increase and decrease during treatment with tamoxifen)
10
100
1000
10000
100000
1000000
-400 -200 0 200 400 600 800 1000 1200 1400
days
c
e
l
l
s
/
m
l
Tamoxifen
10
100
1000
10000
100000
1000000
-400 -200 0 200 400 600 800 1000 1200 1400
days
c
e
l
l
s
/
m
l
Tamoxifen
Relapse after
849d
Relapse after
1112d
Relapse after
627d
a
b
Fig. 3 Kaplan–Meier relapse-free survival curves of patients with
increasing (red line) and decreasing (green line) CETC numbers dur-
ing tamoxifen treatment (P < 0.001 hazard ratio = 5.5). Patients with
no change in cell numbers (thin blue line)826 J Cancer Res Clin Oncol (2011) 137:821–828
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associated with a variety of adverse eVects, including an
increased risk of endometrial cancer and thromboembolic
events. It would, therefore, be desirable to deWne earlier
and more accurately the subgroup of patients who beneWt
from this treatment and those not or no longer beneWting
from tamoxifen in order to provide them with the best ther-
apy in good time.
In the present report, we have extended CETC monitor-
ing, the value of which was established during neoadjuvant
and adjuvant chemotherapy, to adjuvant hormone therapy.
In contrast to the rapid response of CETC to chemotherapy,
during tamoxifen therapy, we observed a slow, continuous
change in CETC numbers over several years decreasing or
increasing. This is compatible with the results of cell cul-
ture analysis, where cells are driven into the G0/G1 phase
of the cell cycle by tamoxifen, rather than cell killing
(Osborne 1998).
Patients with increasing numbers of CETC under tamox-
ifen therapy clearly had a signiWcantly higher (5.5-fold) risk
for relapse than those with decreasing CETC. Although it
was not the aim of this work to provide an additional prog-
nostic marker, the increase in CETC during tamoxifen ther-
apy turned out to be the most signiWcant independent
prognostic factor in our patient sample which, although
small, was distributed in prognostic factors similar to other
larger studies. Rather, we aimed at developing a diagnostic
tool for therapy monitoring and, we were indeed able to
show that, in the absence of overt metastases, an increase in
CETC during tamoxifen treatment is the earliest indicator
of therapy resistance.
Patients with relapse in spite of decreasing CETC had
already had a massive leachate of tumor cells during sur-
gery. Such cells may have had the opportunity to settle and
grow into metastases already before the start of tamoxifen
therapy. In these patients with peripherally circulating cells
still responsive to therapy, the metastases obviously did not
respond to tamoxifen, probably due to resistance mecha-
nisms developing in the metastases. If it turns out that one
of the main actions of tamoxifen is to prevent circulating
tumor cells from settling, then it would be meaningful to
apply it early during treatment. Unfortunately, a direct
comparison between the cells in the metastases and the
circulating cells was not performed; this will be the aim of
further research.
Most of the relapses occurred in patients with increas-
ing CETC despite tamoxifen. Therefore, this method
makes it possible to identify patients at high risk for
progression early in the course of the disease and
Table 2 DiVerences between relapsing patients and patients in com-
plete continuous remission with respect to age, tumor size, lymph
nodes, HER2/neu status, hormone receptor and chemotherapy
CR complete remission, Rel relapse, adj adjuvant, neo neoadjuvant,
n.a. not analyzed
CR Rel P
Number of patients 132 (75%) 43 (25%)
Mean age 51  53 ns
Tumor size
T1 71 (54%) 20 (46%) 0.45 ns
T2> 49 (37%) 18 (42%)
n.a. 12 (9%) 5 (12%)
Node
N0 87 (66%) 16 (37%) 0.005
N1> 33 (25%) 23 (54%)
n.a. 12 (9%) 4 (9%)
Her2/neu status
Negative 62 (47%) 21 (49%) ns
Positive 31 (23%) 11 (25.5%)
n.a. 39 (30%) 11 (25.5%)
Hormone receptor
Negative 8 (6%) 1 (2%) ns
Positive 115 (87%) 40 (93%)
n.a. 9 (7%) 2 (5%)
Chemotherapy
Adj 51 (39%) 22 (51%) ns
Neo 31 (23%) 10 (23%)
None 38 (29%) 8 (19%) 0.12 ns
n.a. 12 (9%) 3 (7%)
Patients with CETC analysis 121 (82%) 26 (18%)
Decrease 64 (52%) 2 (11%) <0.0001
Increase 37 (30%) 21 (81%)
No change 20 (16%) 3 (8%)
Fig. 4 Kaplan–Meier relapse-free survival curves of patients during
treatment with aromatase inhibitors who had had increasing (red line)
or decreasing (green line) CETC numbers during tamoxifen treatment,
all patients (P =0 . 0 0 4 )J Cancer Res Clin Oncol (2011) 137:821–828 827
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quickly identify an inactive treatment regimen without
requiring lengthy studies using survival endpoints.
Apart from mechanisms postulated as being responsible
for tamoxifen resistance (EBCTCG 1998; Osborne
1998; Hind et al. 2007; Jordan 2008), tamoxifen discon-
tinuation may also play a role, particularly in elderly
patients (Gaston and Kolesar 2008). Therefore, at times
we  Wnd decreasing CETC numbers followed by a re-
increase that may indicate tamoxifen resistance, but may
also be due to failed compliance to tamoxifen. Gauging
the behavior of their CETC might help to convince
patients to take a medication that otherwise seems to
have no immediate positive eVect and eventually also
help to decide when unnecessary medication can be ter-
minated.
The increase in CETC during tamoxifen therapy was,
however, also a highly signiWcant predictor of relapse
during subsequent treatment with AI. Some patients after
relapse during tamoxifen can be kept in long-lasting pro-
gression-free status with AI. Some tamoxifen-resistant
patients, possibly those with CYP2D6 deWciency may
even be rescued by treatment with AI. Some of our
patients were only switched to AI after developing metas-
tases. It will be one of the main advantages of this new
tool of CETC quantiWcation that treatment results might
be additionally improved if patients are switched to a bet-
ter working treatment before the manifestation of metasta-
ses, and a switch to other treatment options available
should be taken into consideration already at this point in
time. CETC monitoring during hormone therapy would,
thus, help in the decision of the appropriate time for
changing therapies and help to increase the compliance of
hormone therapy.
With many issues regarding the adjuvant use of hor-
mone treatment remaining unsettled, such as the optimal
duration of treatment or the optimal sequencing of
tamoxifen with AI, CETC monitoring will, for the Wrst
time, provide a tool applicable to the individual patient
to better control and tailor hormone therapy according to
the patients’ requirements, beneWting not only patients
in complete remission but also patients who have
already suVered relapse (Cianfrocca and Gradishar
2005).
This method could also contribute to trials in male
androgen-dependent tumors (Souhami et al. 2009), giving
reliable data, in order to tailor adjuvant endocrine treatment
to the needs of the individual patient.
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